Neurological Complications Comparing Endoscopically vs. Open Harvest of the Radial Artery (NEO)

March 13, 2021 updated by: Christian Lildal Carranza, Rigshospitalet, Denmark

Endoscopic Versus Open Radial Artery Harvest and Mammario-radial Versus Aorto-radial Grafting in Patients Undergoing Coronary Artery Bypass Surgery (The 2x2 Factorial Designed Randomised NEO Trial)

Coronary artery bypass grafting (CABG) using the radial artery (RA) has since the nineties gone through a revival. The initially reported worse outcome in RA graft patients compared to patients grafted with the saphenous vein (SV) has since been corrected. Studies have shown better patency when using RA, so the RA is going to be preferred more and more especially in younger patients where long time patency is critical. During the last 10 years endoscopic techniques to harvest the RA have evolved. Multiple different techniques have been used, but now the equipment and technique have been refined and are highly reliable. The investigators hypothesize that the endoscopic technique has less complications and a just as good patency as open harvest. There are also two possible ways to use the RA as a graft. One way is sewing it onto the aorta and another way is sewing it onto the mammarian artery. The investigators hypothesize that using it on the mammarian artery is superior as a revascularisation technique with just as good a patency as sewing it directly onto the aorta.

Study Overview

Detailed Description

Objectives

The present trial will in patients undergoing CABG (1) evaluate the complications in endoscopic versus traditionally harvested radial arteries, (2) evaluate graft patency in endoscopic harvested radial arteries versus open technique, and (3) evaluate the use of mammario-radial grafting versus aorto-radial grafting.

Design and trial size

The NEO Trial is a randomised clinical trial with a 2x2 factorial design. We plan to randomise 300 participants into four intervention groups: (1) mammario-radial endovascular group; (2) aorto-radial endovascular group; (3) mammario-radial open group and (4) aorto-radial open group. A subgroup of 100 participants will be selected to undergo a special scanning of the vascular perfusion of donor and control hands (MIBI scan). The evaluation of graft patency and ischaemia in the arm will be blinded but the assessment of the primary outcome of handfunction at three months is non-blinded evaluated by questionnaire.

Trial interventions

Trial 1: The experimental procedure in this trial will be endoscopic radial artery harvest (ERAH). The control intervention will be open radial artery harvest (ORAH).

Trial 2: The experimental procedure in this trial will be the technique where the radial artery is sewn onto the mammarian artery as a mammario-radial anastomosis (composite/Y-graft). The control intervention will be the technique of sewing the radial artery directly onto the aorta as an aorto-radial anastomosis (free radial artery).

Inclusion and exclusion criteria

All patients referred to our department for sub acute or elective coronary bypass operation will be eligible for trial inclusion. Inclusion criteria are: 18 years or older; able and willing to give informed consent; multi-vessel disease. Exclusion criteria are: off-pump procedure; multi-procedure (i.e. concomitant valve surgery); contrast allergy; geographically not available for follow-up; Allen's test with insufficient ulnary artery perfusion; no informed consent; acute operation; dialysis; preoperative neurological deficit on the donor arm; left ventricle ejection fraction (LVEF) less than 20%; former sternotomy and malignant disease.

Primary and secondary outcomes

Trial 1: The primary outcome will be evaluation of hand function at three months.

The secondary outcomes will be: occurrence of neurophysiological defects in the donor arm assessed by examination of cutaneous sensibility and measurements of the sensory and motoric nervous conduction velocity preoperatively and after three months; change in subjective cutaneous sensibility assessed by a clinical examination after three months; complications assessed as a composite of haematoma formation, wound dehiscence or infection registered before discharge and after three months.

We will also assess a number of exploratory outcomes (serious adverse events, reoperation for bleeding, revascularisation, myocardial infarction, stroke or death, handgrip strength, muscular function in the hand, scar evaluation, vascular supply to the hand, graft patency and participants subjective evaluation of hand function after 1 year).

Trial 2: The primary outcome will be the occurrence of cardio- or cerebrovascular events during the first year after surgery comparing mammario-radial versus aorto-radial grafts. As an exploratory outcome we will also assess graft patency by multi-slice computer tomography (MSCT) comparing mammarioradial versus aortoradial grafts one year after surgery.

Time schedule

Randomisation will commence after 15th of May 2013. The inclusion period of altogether 300 participants is expected to last three years.

Study Type

Interventional

Enrollment (Actual)

301

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2100
        • Rigshospitalet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Elective/sub acute CABG as an isolated procedure.
  • Age > 18 years
  • Multi-vessel disease
  • Non-dominant arm is eligible for radial artery harvest
  • Written informed consent

Exclusion Criteria

  • Geographically not available for follow up
  • Modified Allen's test indicating insufficient ulnary artery perfusion
  • Valve surgery, ablation surgery or any kind of concomitant surgery during same admission.
  • Acute operation (<24 hours from admission)
  • Dialysis
  • Preoperative neurological deficit on the donor arm
  • LVEF < 20% preoperative
  • Former sternotomy
  • Contrast allergy
  • Malignant disease
  • No written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Grp 1: ERAH, Mammarioradial (Y-graft)
Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
Radial artery harvest is performed as an endoscopic procedure.
The radial artery is used as an composite graft positioned on the internal mammarian artery.
Other: Grp 2: ERAH, Aortoradial (Free RA)
Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
Radial artery harvest is performed as an endoscopic procedure.
The radial artery is used as an free graft positioned on the aorta.
Other: Grp 3: ORAH, Mammarioradial (Y-graft)
Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
The radial artery is used as an composite graft positioned on the internal mammarian artery.
Radial artery harvest is performed as an open procedure.
Other: Grp 4: ORAH, Aortoradial graft (Free RA)
Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
The radial artery is used as an free graft positioned on the aorta.
Radial artery harvest is performed as an open procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sum score of hand function questionnaire
Time Frame: 3 months postoperatively
Using Likert-type scale scoring system quality of life is assessed after radial artery harvest. The mean values in the ERAH group will be compared to the mean value in the ORAH group at three months after surgery.
3 months postoperatively
Occurence of cardiac and cerebrovascular events in aortoradial versus mammarioradial grafting
Time Frame: 1 year postoperatively
Occurrence of one of the following cardiac or cerebrovascular events: all cause mortality, myocardial infarction (MI), target vessel revascularisation (TVR) or stroke at one year postoperatively will be compared.
1 year postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complications in the donor arm in ERAH versus ORAH
Time Frame: 3 months postoperatively
Occurrence of complications at three months after surgery. Complications are defined as a composite of haematoma formation, wound dehiscence, or infection will be compared.
3 months postoperatively
Clinical neurological examination in donor arm ERAH versus ORAH
Time Frame: 3 months postoperatively
Clinical examination of subjective cutaneous sensibility will be compared between ERAH versus ORAH groups.
3 months postoperatively
Neurological deficits in ERAH versus ORAH
Time Frame: 3 months postoperatively

Occurence of deficits in following neurological exams will be compared between ERAH and ORAH

  1. Cutaneous sensibility on both forearms and hands by appraisal of dermatomes. All sensibility modalities are examined:

    1. Cutaneous touch sensibility examined by Von Fray hair
    2. Deep pain sensibility examined by algometry.
  2. Sensory nervous conduction velocity examined on both forearms and hands:

    1. N. medianus (dig. II - hdl); orthodromic technique
    2. N. ulnaris (dig. V - hdl); orthodromic technique
    3. N. radialis (antebrachium - tabatiere); antidromic technique
    4. N. cutaneous antebrachium lateralis (elbow - antebrachium); antidromic technique
    5. N. cutaneous antebrachium medialis (elbow - antebrachium); antidromic technique
  3. Motoric nervous conduction velocity examined on both forearms and hands:

    1. N. medianus (hdl - m. abductor policis brevis (APB), elbow - APB)
    2. N. ulnaris (hdl - m. abductor digiti minimi)
3 months postoperatively

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vascular function in the donor arm of the ERAH and ORAH groups compared to non-donor arms.
Time Frame: 3 months postoperatively
MIBI scan after exercise induced relative ischemia will be compared between donor versus non-donor arms.
3 months postoperatively
Graft patency in ERAH versus ORAH
Time Frame: 1 year postoperatively
MSCT will be used to evaluate patency.
1 year postoperatively
Graft patency in aortoradial versus mammarioradial grafting
Time Frame: 1 year postoperatively
MSCT will be used to evaluate patency.
1 year postoperatively
Change in handgrip strength
Time Frame: the day before surgery and 1 year postoperatively.
Change in handgrip strength will be measured in the conduit donor arm and compared between ERAH versus ORAH.
the day before surgery and 1 year postoperatively.
Change in muscular function in ERAH versus ORAH
Time Frame: the day before surgery and 1 year postoperatively

Following muscles are rated according to the Oxford Scale for grading muscle strength (see table 7) the day before surgery and at one year postoperatively:

  • m. abductor pollicis brevis
  • m. abductor digiti minimi
  • mm. interosseus palmares
  • m. flexor digitorum profundus II+V
  • m. extensor digitorum The change in muscular function will be compared between ERAH versus ORAH.
the day before surgery and 1 year postoperatively
Serious adverse events in ERAH versus ORAH
Time Frame: 1 year postoperatively
Occurrence of the following serious adverse events at time point one year after surgery: reoperation for bleeding; revascularisation; myocardial infarction; stroke; or death will be compared between ERAH and ORAH.
1 year postoperatively
Scar evaluation in ERAH versus ORAH
Time Frame: 1 year postoperatively
Using Stony Brooke Scar Evaluation Score the scars will be evaluated and the mean scores compared between ERAH versus ORAH groups.
1 year postoperatively
Neuropathic pain symptoms and signs in ERAH versus ORAH
Time Frame: 3 months postoperatively
The Leeds assessment of neuropathic symptoms and signs (LANNS) pain scale will be used after 3 months to compare pain in ERAH versus ORAH groups.
3 months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christian L Carranza, MD, Department of Cardio-Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Peter Skov Olsen, MD DMSc, Department of Cardio-Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Christian Gluud, MD DMSc, Copenhagen Trial Unit, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Martin Ballegaard, MD PhD, Department of Clinical Neurophysiology, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Philip Hasbak, MD PhD, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Andreas Kjær, Prof MD DMSc, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Klaus F Kofoed, MD DMSc, Department of Cardiology and Radiology, Rigshospitalet, Copenhagen, Denmark
  • Study Chair: Mads Werner, MD, DMSc, Multidisciplinary Pain Centre, Rigshospitalet, Copenhagen, Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2013

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

November 1, 2020

Study Registration Dates

First Submitted

February 25, 2013

First Submitted That Met QC Criteria

May 5, 2013

First Posted (Estimate)

May 8, 2013

Study Record Updates

Last Update Posted (Actual)

March 17, 2021

Last Update Submitted That Met QC Criteria

March 13, 2021

Last Verified

March 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Ischemia

Clinical Trials on Endoscopic radial artery harvest

Subscribe